Dole Food Company Releases 2020 Corporate Responsibility & Sustainability Report
Dole Food Company announced today the release of its 2020 Corporate Responsibility & Sustainability Report. The report unveils the organization’s new sustainability framework, “The Dole Way,” along with the company’s first-ever enterprise-wide sustainability goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005205/en/
Dole Fresh Fruit, Pineapple Farm (Photo: Business Wire)
“Since our founding, Dole has strived to deliver the best of which we are capable—in both our products and how we produce them,” stated Johan Linden, CEO of Dole. “The need for healthy food choices has never been more evident than during these past weeks as we adapt under this global pandemic. The journey and dedication to be a responsible citizen of our communities as well as a good steward of our land will continue into our future and Dole will remain steadfast in being honest and transparent about our efforts and our impacts in supplying wholesome food across the globe.”
“Of course,” Linden continued, “our stakeholders expect this of us, but even more we expect this of ourselves; to engage in open dialogue, including critical voices, to make a measurable and meaningful difference for people and the planet, and to constantly evaluate and improve. It’s what we believe is the right way to do business.”
Dole’s sustainability report outlines an ambitious slate of initiatives under the Dole Way framework focused on tangible action directed towards five key goals:
- More than ever, Dole understands our responsibility to positively impact underserved communities and promises to donate no less that 2,500 tons of fresh fruit and produce by 2025.
- Dole will effect valuable long-term change by declaring a social premium for Dole branded bananas and pineapple. This social investment will be directed by company organizations and independent foundations that have operated in Dole’s Latin American production areas for decades and will be invested in the communities according to local needs.
- Dole produce is grown in areas where water is becoming increasingly scarce, and Dole is committed to reduce water usage while improving water quality in its operations.
- Dole will continue to take action to promote healthy eating and nutrition education, with a special focus on youth. At its core, this is a promise to support people living longer and healthier lives.
- Dole recognizes that climate change is real and that the food and agriculture industries have a role to play in mitigating its effects. Dole will focus on decreasing its carbon footprint by ensuring new vessels include efficiency upgrades and working towards achieving net zero carbon emissions at farm level by 2030.
Other important sustainability targets include ensuring all packaging materials used in Dole’s banana and pineapple businesses are either recyclable or compostable by 2025, and introducing blockchain or similar technology in all operations to bring about a step-change in food safety and transparency.
Reporting on the impacts of Dole’s responsibility and sustainability goals is also of critical importance.
“This report and our goals are a new milestone in our sustainability pursuit, and farming is at the heart of that transformation. As farmers, we are facing the reality of climate change and are joining all other concerned people and businesses willing to tackle this challenge in our supply chain,” said Xavier Roussel, Vice President of Sustainability. “We will build on our learning—both in precision farming and organic agriculture—to deliver on our commitments in alliance with our business partners and other stakeholders. As an employer we will continue to make a difference in the lives of our employees and local communities and make a positive impact both within our farm borders and beyond.”
Added Roussel, “Dole is absolutely committed to being part of the community of concerned citizens taking on the sustainability challenge.”
To view all Dole’s achievements and goals click the link to the 2020 Corporate Responsibility & Sustainability Report click here.
About Dole Food Company
Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005205/en/
Contact information
US Contact: William Goldfield
818-874-4647
william.goldfield@dole.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
